Online Programme
Search for the sessions or presentations
Session Type
Lunch Symposium
Channel
Live streaming channel 3
PP-PRIM-ALL-0152-1 July 2020
[{"name":"SY 1 - BAYER: Primovist 2020: how the choice of MR contrast agent influences the management of patients with liver diseases","mode":"stream"}]
{"type":6,"code":"7E72WM02u"}
[{"name":"SY 1.1 - Introduction \u003Csmall\u003E(ID 1155)\u003C\/small\u003E","mode":"","public":true,"info":{"id":1155,"presentation":"SY 1.1 - Introduction \u003Csmall\u003E(ID 1155)\u003C\/small\u003E","session":"SY 1 - BAYER: Primovist 2020: how the choice of MR contrast agent influences the management of patients with liver diseases","presenter":"G. Brancatelli, Palermo, IT","photo":""},"playlist":[{"name":"Bayer Symposium","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/bayer complience slide.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/esgar2020\/86\/bayer complience slide.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/E4F13E5C.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/bayer complience slide.vtt"},{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1155_2p.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1155_2p.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/35FE9A29.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1155_2p.vtt","thumbnails":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1155_2p-thumbnails.vtt"}]},{"name":"SY 1.2 - Primovist matters in the cirrhotic patients \u003Csmall\u003E(ID 1156)\u003C\/small\u003E","mode":"","public":true,"info":{"id":1156,"presentation":"SY 1.2 - Primovist matters in the cirrhotic patients \u003Csmall\u003E(ID 1156)\u003C\/small\u003E","session":"SY 1 - BAYER: Primovist 2020: how the choice of MR contrast agent influences the management of patients with liver diseases","presenter":"G. Brancatelli, Palermo, IT","photo":""},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1156_1p.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1156_1p.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/3DE5EF64.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1156_1p.vtt","thumbnails":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1156_1p-thumbnails.vtt"}]},{"name":"SY 1.3 - Primovist matters in the non-cirrhotic patients \u003Csmall\u003E(ID 1157)\u003C\/small\u003E","mode":"","public":true,"info":{"id":1157,"presentation":"SY 1.3 - Primovist matters in the non-cirrhotic patients \u003Csmall\u003E(ID 1157)\u003C\/small\u003E","session":"SY 1 - BAYER: Primovist 2020: how the choice of MR contrast agent influences the management of patients with liver diseases","presenter":"M. Karcaaltincaba, Ankara, TR","photo":""},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1157_2p.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1157_2p.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/77DB9D54.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1157_2p.vtt","thumbnails":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1157_2p-thumbnails.vtt"}]},{"name":"SY 1.4 - Questions & answers \u003Csmall\u003E(ID 1158)\u003C\/small\u003E","mode":"","public":true,"info":{"id":1158,"presentation":"SY 1.4 - Questions & answers \u003Csmall\u003E(ID 1158)\u003C\/small\u003E","session":"SY 1 - BAYER: Primovist 2020: how the choice of MR contrast agent influences the management of patients with liver diseases","presenter":"","photo":""},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1158_1p.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1158_1p.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/286FFD56.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1158_1p.vtt","thumbnails":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1158_1p-thumbnails.vtt"}]}]
{"type":2,"code":"8E32WM02u"}
[session]
[presentation]
[presenter]
SY 1.1 - Introduction (ID 1155)
Lecture Time
15:00 - 15:03
Presentation Number
SY 1.1
Session Type
Lunch Symposium
Channel
Live streaming channel 3
[{"name":"SY 1.1 - Introduction \u003Csmall\u003E(ID 1155)\u003C\/small\u003E","mode":"","public":true,"info":{"id":1155,"presentation":"SY 1.1 - Introduction \u003Csmall\u003E(ID 1155)\u003C\/small\u003E","session":"SY 1 - BAYER: Primovist 2020: how the choice of MR contrast agent influences the management of patients with liver diseases","presenter":"G. Brancatelli, Palermo, IT","photo":""},"playlist":[{"name":"Bayer Symposium","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/bayer complience slide.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/esgar2020\/86\/bayer complience slide.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/E4F13E5C.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/bayer complience slide.vtt"},{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1155_2p.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1155_2p.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/35FE9A29.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1155_2p.vtt","thumbnails":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1155_2p-thumbnails.vtt"}]}]
{"status_url":"https:\/\/cslide.ctimeetingtech.com\/play\/6E22WM0kV\/status","status":20,"track_url":"https:\/\/cslide.ctimeetingtech.com\/play\/6E22WM0kV\/track","track":60,"provider":"CTI","provider_live":0,"type":1,"code":"6E22WM0kV"}
[session]
[presentation]
[presenter]
Collapse
SY 1.2 - Primovist matters in the cirrhotic patients (ID 1156)
Lecture Time
15:03 - 15:21
Presentation Number
SY 1.2
Session Type
Lunch Symposium
Channel
Live streaming channel 3
[{"name":"SY 1.2 - Primovist matters in the cirrhotic patients \u003Csmall\u003E(ID 1156)\u003C\/small\u003E","mode":"","public":true,"info":{"id":1156,"presentation":"SY 1.2 - Primovist matters in the cirrhotic patients \u003Csmall\u003E(ID 1156)\u003C\/small\u003E","session":"SY 1 - BAYER: Primovist 2020: how the choice of MR contrast agent influences the management of patients with liver diseases","presenter":"G. Brancatelli, Palermo, IT","photo":""},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1156_1p.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1156_1p.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/3DE5EF64.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1156_1p.vtt","thumbnails":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1156_1p-thumbnails.vtt"}]}]
{"status_url":"https:\/\/cslide.ctimeetingtech.com\/play\/7E22WM0kW\/status","status":20,"track_url":"https:\/\/cslide.ctimeetingtech.com\/play\/7E22WM0kW\/track","track":60,"provider":"CTI","provider_live":0,"type":1,"code":"7E22WM0kW"}
[session]
[presentation]
[presenter]
Collapse
SY 1.3 - Primovist matters in the non-cirrhotic patients (ID 1157)
Lecture Time
15:21 - 15:38
Presentation Number
SY 1.3
Session Type
Lunch Symposium
Channel
Live streaming channel 3
[{"name":"SY 1.3 - Primovist matters in the non-cirrhotic patients \u003Csmall\u003E(ID 1157)\u003C\/small\u003E","mode":"","public":true,"info":{"id":1157,"presentation":"SY 1.3 - Primovist matters in the non-cirrhotic patients \u003Csmall\u003E(ID 1157)\u003C\/small\u003E","session":"SY 1 - BAYER: Primovist 2020: how the choice of MR contrast agent influences the management of patients with liver diseases","presenter":"M. Karcaaltincaba, Ankara, TR","photo":""},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1157_2p.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1157_2p.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/77DB9D54.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1157_2p.vtt","thumbnails":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1157_2p-thumbnails.vtt"}]}]
{"status_url":"https:\/\/cslide.ctimeetingtech.com\/play\/8E22WM0kX\/status","status":20,"track_url":"https:\/\/cslide.ctimeetingtech.com\/play\/8E22WM0kX\/track","track":60,"provider":"CTI","provider_live":0,"type":1,"code":"8E22WM0kX"}
[session]
[presentation]
[presenter]
Collapse
SY 1.4 - Questions & answers (ID 1158)
Lecture Time
15:38 - 15:45
Presentation Number
SY 1.4
Session Type
Lunch Symposium
Channel
Live streaming channel 3
[{"name":"SY 1.4 - Questions & answers \u003Csmall\u003E(ID 1158)\u003C\/small\u003E","mode":"","public":true,"info":{"id":1158,"presentation":"SY 1.4 - Questions & answers \u003Csmall\u003E(ID 1158)\u003C\/small\u003E","session":"SY 1 - BAYER: Primovist 2020: how the choice of MR contrast agent influences the management of patients with liver diseases","presenter":"","photo":""},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1158_1p.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1158_1p.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/286FFD56.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1158_1p.vtt","thumbnails":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/esgar2020\/86\/v\/1158_1p-thumbnails.vtt"}]}]
{"status_url":"https:\/\/cslide.ctimeetingtech.com\/play\/9E22WM0kY\/status","status":20,"track_url":"https:\/\/cslide.ctimeetingtech.com\/play\/9E22WM0kY\/track","track":60,"provider":"CTI","provider_live":0,"type":1,"code":"9E22WM0kY"}
[session]
[presentation]
[presenter]
Collapse